BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27885456)

  • 1. [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
    Autenrieth ME; Horn T; Kurtz F; Nguyen K; Morgenstern A; Bruchertseifer F; Schwaiger M; Blechert M; Seidl C; Senekowitsch-Schmidtke R; Gschwend JE; Scheidhauer K
    Urologe A; 2017 Jan; 56(1):40-43. PubMed ID: 27885456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
    Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
    Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Mostafid H
    Int J Urol; 2010 Sep; 17(9):766-7. PubMed ID: 20727047
    [No Abstract]   [Full Text] [Related]  

  • 7. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
    Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
    J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
    Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
    Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicoureteral reflux after intravesical instillation of bacillus Calmette-Guérin against carcinoma in situ of the bladder.
    Morita T; Tokue A
    Urol Int; 2004; 73(3):287-8. PubMed ID: 15539855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.